Key differences between Clinical Trials and Clinical Studies

Understanding the distinction between clinical trials and clinical studies is vital in the realm of medical research. While all clinical trials fall under the broader category of clinical studies, the two are not synonymous. Clinical trials specifically focus on testing new treatments or interventions through controlled experiments involving human volunteers, whereas clinical studies encompass a wider range of research activities.

Clinical studies refer to investigations that examine how a medicine works, its potential side effects, and how the body processes it. The primary aim is to determine the medicine’s safety and effectiveness. Researchers analyse various aspects such as how the medicine is absorbed, distributed, metabolised, and excreted by the body, alongside any possible adverse reactions, ensuring that the medicine is safe for patients.

A clinical trial, as a subset of clinical studies, plays a crucial role in bringing new medical treatments, drugs, or procedures to the market. These trials involve human volunteers in rigorously controlled environments to assess the safety and effectiveness of the interventions being tested. The distinction between clinical trials and clinical studies lies not only in their scope but also in their objectives, methodologies, and participant requirements.

Clinical studies can be either observational or interventional. Clinical trials fall under the interventional category, as they involve testing a specific intervention in a controlled setting to evaluate its effects. Conversely, observational studies monitor participants and record the outcomes of their current treatments without making any alterations. This approach allows researchers to collect data on the effectiveness of treatments in real-world settings, without introducing new variables.

The objectives of clinical trials and clinical studies also differ. The primary goal of a clinical trial is to determine whether a new intervention is more effective than existing treatments and to assess its safety within a specific population. On the other hand, clinical studies aim to identify patterns, risk factors, or associations between variables and health outcomes. These studies may explore the incidence and prevalence of diseases, as well as identifying potential risk factors and trends.

The phases and types of research involved also distinguish the two. Clinical trials proceed through various phases, each designed to assess different aspects of the intervention’s efficacy and safety. In contrast, clinical studies can take many forms, such as case studies, ecological studies, cross-sectional studies, case-control studies, and cohort studies. Each type of study is used in different research contexts, depending on the research question being addressed.

Participants in clinical trials and clinical studies vary significantly. Clinical trials usually require a large number of participants, selected based on strict eligibility criteria, such as age, health status, and medical history. In contrast, clinical studies may involve a smaller group of participants, especially in case studies, which might focus on detailed observations of just one or a few patients.

Examples of clinical studies include epidemiological studies, which track disease prevalence, and case-control studies, which compare patients with a condition to those without it. Clinical trials, on the other hand, test new treatments in controlled settings. For instance, FluCamp has conducted trials such as flu clinical trials to evaluate new treatments and vaccines for influenza, asthma trials to study medications for managing symptoms, and COVID-19 vaccine trials to assess vaccines’ effectiveness in preventing the virus.

The distinctions between clinical trials and clinical studies highlight the complexity and importance of different research approaches in advancing medical knowledge and improving patient care. Each plays a unique role in the ongoing effort to develop safer and more effective treatments.

hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    Virus portfolio for RSV research and development

    Respiratory Syncytial Virus (RSV), discovered in 1956, is a common and contagious RNA virus responsible for a range of respiratory illnesses worldwide. Initially identified by Dr. Robert Chanock and colleagues in chimpanzees, RSV belongs to the

    hVIVO plc

    Clinical trial eligibility: Pre-screening and Screening

    In clinical trials, ensuring patient safety is paramount, and researchers must identify suitable participants who meet specific requirements. To this end, there are distinct processes involved, known as pre-screening and screening, which help determine whether a

    hVIVO plc

    Connecting Airway Epithelial Cell Models with Human Challenge Studies

    Airway epithelial cells cultured in Air–Liquid Interface (ALI) conditions provide an environment that closely resembles the human airway system. This method facilitates improved oxygen availability and supports cellular differentiation, replicating the physiological conditions of the human

    hVIVO plc

    Esmée shares her FluCamp clinical trial volunteer experience

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Overcoming challenges in high-growth regulated industries

    The Navigating Risk podcast recently explored the challenges faced by high-growth businesses operating in highly regulated industries, particularly life sciences. Helen Yates, the Editor of Global Thought Leadership, engaged in a conversation with Mo Khan, the

    hVIVO plc

    Take a 360° interactive tour of a FluCamp Volunteer Room

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Clinical trial approval process in the UK

    The process of obtaining approval for clinical trials is comprehensive, as it involves multiple regulatory bodies that ensure the safety and efficacy of the medical interventions being tested. Researchers begin by meticulously planning the trial, outlining

    hVIVO plc

    hVIVO reports positive results from RSV antiviral human challenge trial

    hVIVO plc (LON:HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has noted the announcement by Enanta Pharmaceuticals, reporting positive topline results from

    hVIVO plc

    The importance of Clinical Trial Monitoring

    Monitoring is essential from the moment a clinical trial is planned until it concludes. This ensures that the study remains unbiased, patient safety is prioritised, and accurate results are achieved. The process of clinical trial monitoring

    hVIVO plc

    The future of vaccine development through human challenge trials

    Testing new treatments and vaccines often requires years, if not decades, to gather sufficient data. In response, scientists are turning to a more direct approach that involves deliberately infecting volunteers with potentially deadly pathogens. A notable

    hVIVO plc

    The impact of Clinical Trial results on medical advancements

    Clinical trials play a pivotal role in advancing the medical industry by allowing new treatments and interventions to be rigorously tested for both effectiveness and safety. Understanding how clinical trial data is used is essential to

    hVIVO plc

    Hvivo reports significant growth in earnings and revenue

    Hvivo, previously known as Open Orphan, saw a significant increase in earnings during the first six months of the year, marking a 67.6% rise. Earnings before interest, taxes, depreciation, and amortisation reached £8.7 million (€10.32 million),

    hVIVO plc

    hVIVO reports strong first half, delivering record revenues and margins

    hVIVO plc (LON:HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced its unaudited interim results for the six-month period ended 30 June 2024.